Jump to Main Content
Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib
- Veerman, G.D. Marijn, Lam, Mei H., Mathijssen, Ron H.J., Koolen, Stijn L.W., de Bruijn, Peter
- Journal of chromatography 2019 v.1113 pp. 37-44
- acetonitrile, ambient temperature, ammonium, blood, formates, humans, ice, liquids, lithium, pH, tandem mass spectrometry, ultra-performance liquid chromatography
- The development and full validation of a sensitive and selective ultra-performance liquid chromatography/tandem mass spectrometry (UPLC–MS/MS) method are described for the simultaneous analysis of afatinib, alectinib, crizotinib and osimertinib in human lithium heparinized plasma. Afatinib-d6, crizotinib-d5 and erlotinib-d6 were used as internal standards. Given osimertinib's instability in plasma and whole blood at ambient temperature, samples should be solely processed on ice (T = 0 °C). Chromatographic separation was obtained on an Acquity UPLC ® BEH C18; 2.1 × 50 mm, 1.7 μm column, which was eluted with 0.400 mL/minute flow on a linear gradient, consisting of 10 mM ammonium formate (pH 4.5) and acetonitrile. Calibration curves for all compounds were linear for concentration ranges of 1.00 to 100 ng/mL for afatinib and 10.0 to 1000 ng/mL for alectinib, crizotinib and osimertinib, herewith validating the lower limits of quantification at 1.00 ng/mL for afatinib and 10.0 ng/mL for alectinib, crizotinib and osimertinib. Within-run and between-run precision measurements fell within 10.2%, with accuracy ranging from 89.2 to 110%.